URGN FY 2016 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M

Gross Profit

$18M99.8% margin

Operating Income

$798,0004.6% margin

Net Income

-$2M-11.1% margin

EPS (Diluted)

$-0.16

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$23M

Total Liabilities

$7M

Stockholders' Equity

$16M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$0	—
Gross Profit	$18M	-$113,000	+15588.5%
Operating Income	$798,000	-$12M	+106.4%
Net Income	-$2M	-$13M	+84.7%